Abomics PGx is a service that interprets the complex pharmacogenetic data and offers laboratories, clinicians and patients an easy access to reliable and highly updated pharmacogenetic information. Abomics PGx makes pre-emptive pharmacogenetic testing cost-effective. With pre-emptive testing personalized medicine becomes reality.Contact us
Abomics PGx provides the clinicians and patients with a state-of-the-art report that is easy to understand and fast to use.
In the report all the drugs with genetic variation regarding the tested genes are listed and categorized by their clinical relevance. All of the genetic tests done to the patient are listed and explained in detail with illustrations. The report also includes detailed recommendations for each drug, so the clinician can adjust the drug and dosing quickly and efficiently.
Reports are approved by medical professionals who take the responsibility for the correctness of the interpretations. Drug-drug interactions can also be integrated to the service upon request.
Abomics PGx is available worldwide and comes with low initial costs and full support. Pricing varies from 50 to 100 € per report, depending on volume and coverage of the panel.
Translating Research into Clinical Practice
Abomics is a health technology firm that provides healthcare professionals with new approaches to personalized medicine. The company was founded in 2013 in Finland and comprises of admitted specialists in several fields of science. Abomics designs cutting-edge integrated decision support tools in collaboration with providers of EHR systems and laboratory IT systems. All Abomics’ products have been designed to meet the extensive requirements of healthcare professionals. Our services have been CE-certified according to EU Medical Device Directive.
Tykistökatu 4 B